Our self-developed SM03 (Suciraslimab) is a global first-in-class anti-CD22 mAb for the treatment of rheumatoid arthritis (RA), other immunological and neuro-immunological diseases. Suciraslimab adopts a novel mechanism of action, which differentiates itself from the current treatments available in the market. Indications include:

• Rheumatoid arthritis (RA)
• Systemic lupus erythematosus (SLE)
• Alzheimer’s Disease
• Sjogren’s syndrome (SS)
• Mild cognitive impairment (MCI)

We are continuing to advance clinical studies of Suciraslimab in other immunological diseases, aiming to expand the potential therapeutic area of Suciraslimab, including Alzheimer’s disease and SLE, to fulfill unmet medical needs and thus further promote the potential for subsequent commercialisation of the products.

SN1011 is our third-generation, covalent reversible BTK inhibitor. SN1011 was designed to exhibit high selectivity with prolonged but controlled drug exposure to achieve superior efficacy and good safety profile for the potentially long-term treatment of other rheumatology or neuro-immunological diseases. Indications include:

• Pemphigus
• Systemic lupus erythematosus (SLE)
• Neuromyelitis optica spectrum disorder (NMOSD)
• Multiple Sclerosis (MS)

SM06 is a second-generation anti-CD22 antibody that is humanized using our proprietary framework-patching technology. SM06 is contemplated to be a less immunogenic and more human-like antibody with improved safety profiles. Indications include:

• Systemic lupus erythematosus (SLE)
• Rheumatoid arthritis (RA)
• Neuromyelitis Optica Spectrum Disorder (NMOSD)
• Sjogren’s syndrome (SS)

SM09 is a framework-patched, humanised anti-CD20 antibody that targets an epitope different from that of other market-approved anti-CD20 antibodies such as rituximab, obinutuzumab and ofatumumab for the treatment of non-Hodgkin's lymphoma and other auto-immune diseases with significant unmet medical needs. Indications include:

• Non-Hodgkin’s lymphoma (NHL)
• Autoimmune Diseases